































































Focus and features of prescribing indications
spanning multiple chronic conditions in
older adults: A narrative review
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Abstract
Background: Inappropriate prescribing is frequent in older adults and associated with adverse outcomes. Prescribing
indications aim to optimize prescribing, but little is known about the focus and features of prescribing indications for
the most common chronic conditions in older adults. Understanding the conditions, medications, and issues addressed
(e.g., patient perspective, drug-disease interaction, adverse drug event) in current prescribing indications may help to
identify missing indications and develop standardized measures to improve prescribing quality.
Methods: We searched Ovid/MEDLINE and EMBASE for articles published between 2015 and 2020 reporting pre-
scribing indications for older adults. Prescribing indication included 1) prescribing “criteria,” or statements that guide
prescribing action, and 2) prescribing “measures,” or prescribing actions observed in a population. We categorized their
focus by conditions, medications and issues addressed, as well as level of evidence provided.
Results: Among 16 sets of prescribing indications, we identified 748 criteria and 47 measures. The most common
addressed medications were antihypertensives, analgesics/antirheumatics, and antiplatelets/anticoagulants. The most
frequently addressed issues were drug-disease interaction, adverse drug event, administration, better therapeutic
alternative, and (co-)prescription omission (20.8–36.1%). Age/functioning, drug-drug interaction, monitoring, and efficacy/
safety ratio were found in only 9.9–16.5% of indications. Indications rarely focused on the patient perspective or issues
with multiple providers.
Conclusion: Most prescribing indications for chronic conditions in older patients are criteria rather than measures.
Indications accounting for patient perspective and multiple providers are limited. The gaps identified in this review may
help improve the development of prescribing measures for older adults and ultimately improve quality of care.
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Introduction
Prescribing is a core element in the chronic care of older
patients, particularly among those with multimorbidity.
Inappropriate prescribing, including the use of inappropri-
ate medications, prescribing omissions, drug-drug or drug-
disease interactions, and prescribing cascades, has been
associated with adverse outcomes.1,2 Inappropriate pre-
scribing and adverse drug events are particularly frequent
in older adults, given the high prevalence of polyphar-
macy and multimorbidity in this population.3,4 Older
patients are particularly vulnerable to adverse drug events
because of altered pharmacokinetics and pharmacody-
namics with aging.5 Further, the use of single-disease
focused guidelines will inevitably exacerbate polyphar-
macy when they are simultaneously applied to older
patients with multimorbidity.6,7
Prescribing indications for older patients have been
developed in attempt to optimize prescribing practices
(e.g., prevent inappropriate polypharmacy). These indica-
tions include: 1) prescribing “criteria,” which are state-
ments that guide prescribing action, and 2) prescribing
“measures” (or indicators), which are prescribing actions
observed in a population. Prescribing criteria include state-
ments such as “stop concomitant use of 2 drugs with
anticholinergic properties” and have been promoted in lists
or compendiums of medications to avoid, such as the
Screening Tool of Older Person’s Prescriptions and Screen-
ing Tool to Alert to Right Treatment (STOPP/START)
Criteria or the American Geriatrics Society Beers Cri-
teria.8,9 Prescribing measures include statements such as
“percentage of patients aged >65 years who have been
prescribed 2 drugs with anticholinergic effects con-
comitantly” and have been promoted by organizations like
the National Committee for Quality Assurance (NCQA)
and the National Institute for Health and Care Excellence
Quality and Outcomes Framework (NICE QOF).10,11
While the term “prescribing indications” is most frequently
used to describe for which conditions or in which situations
a medication should be prescribed, in the current review,
we use this term to describe specifically prescribing criteria
and measures that have been developed to improve pre-
scribing practices.
Non-adherence with prescribing indications has been
associated with adverse outcomes.12 However, to our
knowledge, prescribing indication sets have not yet been
broadly implemented in clinical practice, and inappropriate
prescribing persists as a considerable problem worldwide.
Unlike criteria that are simple recommendations, measures
can be used to track and provide feedback on appropriate
prescribing.13 They are thus more likely to impact prescrib-
ing practices than criteria alone, unless criteria are trans-
formed into measures.14–18 It is thus important to have
prescribing measures for dimensions likely to influence
quality and safety for older patients, particularly those with
multimorbidity. Such dimensions may extend beyond
condition and medication type to include more clinically
cross-cutting issues such as potential for drug-drug or drug-
disease interactions, need for monitoring, influence of age
or functioning, and need for patient input. However, we
currently lack systematically synthesized information
about the dimensions and issues covered by existing pre-
scribing criteria and measures, and whether the measures
that exist cover the broad range of dimensions. Such infor-
mation could guide development of future measures and
interventions to improve a broad range of prescribing prac-
tices for chronic conditions.
Thus, the three aims of this review are to: 1) identify
recently developed or updated sets of prescribing indica-
tions (i.e., criteria and measures) applicable to chronic
medication prescribing for the most common and clinically
significant chronic conditions among older adults; 2) assess
the domains covered by the prescribing indications, and
more specifically by the prescribing measures, particularly
given their potential larger impact on prescribing practices
compared with criteria; and 3) describe and categorize the
focus of the indications based on conditions, medications,
issues addressed (e.g., drug-drug interaction, patient per-
spective, monitoring), and evidence provided.
Methods
Search strategy
We performed a literature search in Ovid/MEDLINE and
EMBASE for articles published between January 1, 2015,
and May 20, 2020 that reported prescribing indications for
chronic medications applicable to the ambulatory care of
adults aged 65 years or older, including medications to stop
and medications to start (detailed search strategy in Sup-
plementary Text S1). We limited the search to 2015 to
focus on the most recent or updated evidence. Prescribing
indications included 1) prescribing “criteria,” or state-
ments that guide prescribing action, and 2) prescribing
“measures,” or prescribing actions observed in a popula-
tion.19 We reviewed articles that published indications
based on guidelines but not disease-specific guidelines
directly from specialty societies. However, we included
single disease-specific sets of indications.
We first selected all publications with at least one pre-
scribing indication that met the inclusion criteria. For each
article that only used previously developed indications, we
searched the reference list to identify the article that
described the actual indication development. We retained
that article if it was published in 2015 or later and had not
yet been identified through the initial literature search.
From the prescribing sets included in the review, we
selected only indications related to one or more of the
following prevalent and clinically significant chronic con-
ditions in older adults: cognitive impairment/Parkinson’s
disease; depression and anxiety; sleep problems; chronic
obstructive pulmonary disease and asthma; atrial
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fibrillation; heart failure; ischemic cardiac, peripheral, or
cerebral vascular disease; hypertension; diabetes mellitus;
osteoporosis; thyroid disorders; peptic-related conditions;
non-peptic gastrointestinal conditions; urinary disorders
(including urinary incontinence, urinary retention, and
prostate disorders); and pain and rheumatic disorders. If a
prescribing set included indications for those conditions, as
well as other conditions, we retained only the indications
specific to the above-mentioned conditions. We included
indications that did not mention a specific condition if the
medication could be used to treat one of the selected con-
ditions (e.g., “stop benzodiazepines”). Finally, we included
indications that were not medication-specific (e.g., “stop
any duplicate medication”). We categorized the prescribing
indications according to conditions mentioned in the indi-
cation (when mentioned) and conditions that could be
treated by the specific medication. An indication could thus
be categorized in several different categories (e.g., “stop
benzodiazepines” was classified in “depression/anxiety”
and “sleep problems”).
Data extraction
The first author (CEA) conducted the literature search and
extracted the data using a standardized database in Micro-
soft Access (Microsoft Office Professional Plus 2016). The
following information was extracted for each article: title,
first author, publication year, development location, name
of the criteria or measure set when available, prescribing
indication type (criteria or measures), development
method (literature review, expert suggestion of indica-
tions, adaptation from previous list, patient interview,
expert panel through RAND Appropriateness Method or
other method20), rationale for including a prescribing
indication (applicability to a specific population or set-
ting, clinical importance, level of evidence), and whether
evidence was provided and/or graded. Data collected on
each individual indication included the conditions, medi-
cations and issues addressed, level of evidence, and
whether the indication was adapted from an indication
listed in another set.
We classified medications into the following groups:
dementia and Parkinson’s disease medications; antipsy-
chotics; antidepressants; hypnotics (including benzodia-
zepines, nonbenzodiazepines, sedative antihistamines
and other sleep medications); pulmonary medications;
antiarrhythmics; antihypertensives; lipid-lowering medi-
cations; antiplatelets/anticoagulants; antidiabetics
(including insulin); osteoporosis medications (including
calcium, vitamin D and antiresorptive agents); thyroid
medications; proton pump inhibitors and antacids; other
gastrointestinal medications; urinary medications; antic-
holinergics; analgesics/antirheumatics; and oral corticos-
teroids. Some indications applied to all medications (e.g.,
“avoid any duplicate prescription”) and were thus not
classified in a specific medication group (classified as
“Not specific” thereafter).
When available in the prescribing sets, the quality of
evidence was captured as: 1) GRADE (Grading of Recom-
mendations Assessment, Development, and Evaluation)
category,21 2) strength of the recommendation according
to the Institute of Medicine (IOM) guidelines,22 and/or
3) reference or type of study provided with the criteria or
measure (review or meta-analysis, randomized controlled
trial, observational study, guidelines, medication formu-
lary, textbook, previous set of indications).
Categorization of the prescribing indications
First, to identify whether the focus was to avoid, adapt, or
start medications, we classified each indication into one
or more of the following broad categories: 1) medication
or medication combination to always avoid, or to avoid for
a specific indication (e.g., “stop beta-blocker in combina-
tion with verapamil or diltiazem,” “stop diuretic as first-
line treatment for hypertension”); 2) medication to avoid in
the presence of a specific disease or condition (e.g., “stop
thiazolidinediones in patients with documented heart fail-
ure,” “avoid antipsychotics in patients with history of
falls”); 3) medication potentially inappropriate unless mod-
ifying the dose and/or timing (e.g., “reduce colchicine dose
by 50% in older adults or in case of renal failure,”
“administer terazosin at bedtime”); 4) medication to start,
including co-medications, i.e. joint prescription of two
medications required (e.g., “start laxatives in patients
receiving opioids regularly,” “start vitamin K antagonists
or direct thrombin inhibitors or factor Xa inhibitors in the
presence of chronic atrial fibrillation”).
Second, we defined more detailed categories to capture
how each indication addressed issues most relevant for
appropriate prescribing in older adults, including issues
related to the patients, prescribers, medications, and condi-
tions. We assessed whether each indication focused on one
or more of the following: 1) patient perspective (prefer-
ences, satisfaction, shared-decision making); 2) prescribing
by multiple providers; 3) administration (dose, treatment
duration, timing, formulation); 4) adverse drug event;
5) age, life expectancy, cognitive or physical functioning;
6) better therapeutic alternative; 7) drug-drug interaction/
inappropriate medication combination; 8) drug-disease
interaction whereby a disease or condition renders the med-
ication inappropriate, or requires renal dose adjustment
(e.g., “thiazolidinediones with documented heart failure,”
“metformin if creatinine clearance <30ml/min”); 9) effi-
cacy/safety ratio; 10) monitoring; 11) prescription or
co-prescription omission (e.g., “co-prescribe laxative with
opioids).”
When similar indications referring to medications of the
same group were listed separately (e.g., each tricyclic anti-
depressant in the EU(7)PIM list),23 we combined them to
eliminate repetition and increase comparability with other
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prescribing sets that already combined such indications
(e.g., the Beers criteria).8
Data analysis
For each individual indication, we summarized
the number of conditions, medications, and issues
addressed. We described frequencies as the percentage
of prescribing sets (number of prescribing sets with a
characteristic, relative to the total number of prescrib-
ing sets), and the percentage of indications (number of
indications with a particular characteristic, relative to
the total number of indications). We used Stata 16
software (Stata-Corp LP, College Station, TX, USA)
for all analyses.
Results
Selection of prescribing sets
We excluded 4,311 out of 4,388 articles identified in Ovid/
MEDLINE and EMBASE after review of the title and/or
abstract, and 27 additional articles upon full-text review
(Figure 1). The 50 remaining articles yielded 16 sets of
indications, including 12 sets of prescribing criteria,8,9,23–33
and 4 sets of prescribing measures.10,19,34,35 Four of these
16 sets were identified by searching the references of
studies employing the indications.10,28,29,33
General characteristics of prescribing sets
Among the 16 sets of indications, 11 (68.8%) were specif-
ically developed for older adults,8,9,23–25,27–31,33 and only 1
(6.3%) was developed for multimorbid patients.32 None of
the sets was specifically developed for adults in advanced
aged groups (e.g., 75 years old) or older adults with
frailty. We extracted 795 indications from these sets (med-
ian 50, range 2–123 indications by prescribing set), includ-
ing 748 (94.1%) prescribing criteria and 47 (5.9%)
measures. Many indications addressed similar issues but
none were identical (same wording or reference). All indi-
cations were developed based on literature review (Table
1). Two sets were based only on guidelines.10,35 One study
also used patient interviews.29 Seven sets, encompassing
421 (53.0%) prescribing indications, were developed in
Europe. Evidence was provided through publication refer-
ences in 475 (62.5%) indications and the GRADE system
and strength of recommendation in 117 (14.7%) indications
from 2 (12.5%) prescribing sets8,28 (Supplementary Table
S1). Among 795 indications, 316 (39.8%) were adapted
Figure 1. Flow-chart of search result.
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from a previous list of criteria, most often from the STOPP/
START or Beers criteria. Further details on the prescribing
sets are provided in Supplementary Table S1.
Chronic conditions and chronic medications
addressed in the indications
The number of conditions addressed in each single indica-
tion ranged from 1 to 9 (mean 1.7), and the number of
medications ranged from 1 to 11 (mean 1.5). Pain and
rheumatic disorders were the most frequent focus, appear-
ing in 167 (21.0%) indications (Figure 2, Supplementary
Table S2, Supplementary Figure S1). Hypertension,
depression/anxiety, cognitive impairment/Parkinson’s dis-
ease, heart failure, vascular disorders, atrial fibrillation, and
sleep problems were addressed in 10.2–16.0% of all indi-
cations. Only 15 (1.9%) indications were not condition
specific. Thyroid disorders were least frequently addressed
(8 [1.0%] indications). Of note, two prescribing sets
focused on a single problem (pain/inflammation and
glucocorticoid-induced osteoporosis).30,35 Antihyperten-
sives were the most frequently addressed medications
(18.6% of indications), followed by analgesics/antirheu-
matics (18.1%), antiplatelets/anticoagulants (11.4%) and
antidepressants (10.9%) (Figure 2, Supplementary Table
S2, Supplementary Figure S1). All other medication groups
were addressed in less than 10% of the indications. Only 16
(2.0%) indications were not specific to a medication.
Issues addressed in the indications
Each indication focused on one or more of the following:
medications to always avoid (368 [46.3%] indications),
medications to avoid with a specific condition (228
[28.7%]), potentially inappropriate medications (106
[13.3%]), and medication to start (159 [20.0%]) (Table
1). We provide the issues addressed in the indications
(Table 2), and numbers of indications addressing each issue
in each prescribing set (Supplementary Table S3).
Table 1. General description of the indications and prescribing sets.
N (%) of 795 indications N (%) of 16 sets
General characteristics
Prescribing criteria (i.e., not a measure) 748 (94.1) 12 (75.0)
Indications of:
Medication to starta 159 (20.0) 14 (87.5)
Medication to always avoid or to avoid for a specific indicationb 368 (46.3) 14 (87.5)
Medication to avoid with a specific disease or conditionc 228 (28.7) 13 (81.3)
Potentially inappropriate medicationd 106 (13.3) 8 (50.0)
Continent of development
Europe 421 (53.0) 7 (43.8)
Asia 231 (29.1) 5 (31.3)
North America 85 (10.7) 2 (12.5)
South America 21 (2.6) 1 (6.2)
Australia 37 (4.6) 1 (6.2)
Method of development
Literature review NA 16 (100.0)
Uptake/adaptation from previous list(s) 316 (39.8) 8 (50.0)
Uptake/adaptation of guidelines only 30 (3.8) 2 (12.5)
Expert panel 690 (86.8) 12 (75.0)
Patient interviews 102 (10.8) 1 (6.2)
Characteristics for inclusion in the set of prescribing indications
Applicability to population/setting NA 9 (56.3)
Clinical importance NA 9 (56.3)
Evidence NA 12 (75.0)
Evidence
Provided 510 (64.2) 10 (62.5)
Graded 117 (14.7) 2 (12.5)
Legend: NA (not available) is mentioned for the indications when the information was not specified for each indication, but only provided as general
information in the prescribing set.
aIncludes potential prescribing omission, and co-prescription required because of another medication.
bIncludes age-related measures, or measures related to medication combination (e.g., “stop beta-blocker in combination with verapamil or diltiazem”;
“avoid statin for primary prevention based on age as single risk factor”).
cRelated to a medication in the presence of a specific disease or severity of disease (e.g., “stop beta blocker with symptomatic bradycardia (<50/min),
type II heart block or complete heart block”).
dMedication potentially inappropriate if there is no adaptation of administration (dose reduction according to renal function, dose adaptation because of
a co-medication, administration timing, e.g. “reduce colchicine dose by 50% in older adults or in case of renal failure”; “administer terazosin at
bedtime”).
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The indications focused primarily on drug-disease inter-
actions (287 [36.1%]), adverse drug events (231 [29.1%]),
administration (215 [27.0%]), better therapeutic alterna-
tives (214 [26.9%]), and (co-)prescription omission (165
[20.8%]) (Table 2). Age/life expectancy/functioning,
drug-drug interaction/inappropriate medication combina-
tion, monitoring, and efficacy/safety ratio were addressed
in 9.9% to 16.5% of all indications. Only 4 (0.5%) indica-
tions were related to patient perspective, and none
addressed prescribing by multiple providers.
Figure 2. Proportions of indications (N¼ 795) addressing specific chronic conditions and medications. Abbreviations: COPD; chronic
obstructive pulmonary disease; GI, gastrointestinal; PPI, proton pump inhibitor. Legend: Conditions and medications are listed by
decreasing prevalence. Percentages are proportions of all indications (N ¼ 795). Antidementia include medications for Parkinson’s
disease. Osteoporosis medication includes calcium/vitamin D and antiresorptive agents. “Not specific” means that the indication does
not address a particular condition or medication (e.g., “Avoid any duplicate medication”).
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Table 2. Issues addressed in the indication, with examples.
Indication focus and examples (reason) N (%) of indications
Drug-disease interaction 287 (36.1)
Avoid thiazolidinediones in heart failure with reduced ejection fraction (promote fluid retention and exacerbate heart failure)
Stop beta-blockers in diabetes mellitus with frequent hypoglycemic episodes (risk of suppressing hypoglycemic symptoms)
Stop metformin if creatinine clearance <30ml/min (risk of lactic acidosis)
Adverse drug event 231 (29.1)
Stop benzodiazepines (sedative, may cause reduced sensorium, impair balance)
Stop neuroleptic drugs (may cause ataxia, Parkinsonism)
Avoid peripheral alpha-1 blockers (high risk of orthostatic hypotension; not first-line treatment for hypertension)
Administrationa 215 (27.1)
Magnesium hydroxide: maximum dose 5ml/8 h
Avoid proton pump inhibitor >8 weeks (long-term high dose associated with Clostridium difficile infection and hip fracture)
Avoid use of inhalation corticosteroid as “if necessary” in chronic obstructive pulmonary disease/asthma
Better therapeutic alternative (explicitly mentioned in the indication) 214 (26.9)
Stop loop diuretic as first-line treatment for hypertension (safer, more effective alternatives available; lack of outcome data)
Avoid oral corticosteroids for osteoarthritis (safer alternatives available; unnecessary exposure to systemic side-effects)
Stop theophylline as monotherapy for COPD (safer, more effective alternative; narrow therapeutic index)
New (co-)prescriptionb 165 (20.8)
Start antidepressant treatment in the presence of major depressive disorder
Start xanthine-oxidase inhibitors (e.g., allopurinol, febuxostat) with a history of recurrent episodes of gout
Recommend vitamin D analogs alone for men/women <50 years with 7.5 mg/day prednisolone (or equivalent) for 3 monthsc
Age/life expectancy/functioningd 131 (16.5)
Avoid statins in primary cardiovascular protection in patients with low life expectancy (<2 years) or advanced dementia
Avoid pioglitazone (age-related risks include bladder cancer, fractures and heart failure)
Avoid opioids with history of falls or fractures (may cause ataxia, impaired psychomotor function, syncope, falls)
Medication interaction/inappropriate combination 114 (14.3)
Stop beta-blocker in combination with verapamil or diltiazem (risk of heart block)
Avoid warfarin with non-steroidal anti-inflammatory drug (increased risk of bleeding)
Stop concomitant use of 2 drugs with anticholinergic properties (risk of increased anticholinergic toxicity)
Monitoringe 93 (11.7)
The percentage of patients with hypothyroidism with thyroid function tests recorded in the preceding 12 monthsc
Deprescribe acetylsalicylic acid for primary prevention if age as only risk factor. Monitor for acute coronary syndrome
Deprescribe bisphosphonates for primary prevention after 5 years of treatment. Monitor for new fracture over 1 year
Efficacy/safety ratiof 79 (9.9)
Avoid digoxin for heart failure with preserved systolic ventricular function (no clear evidence of benefit)
Avoid prasugrel (unfavorable risk/benefit profile, especially for adults aged 75 years and older)
Stop any drug prescribed without an evidence-based clinical indication
Patient perspectiveg 4 (0.5)
The patient was not asked which aspects of pharmaceutical care could be improved for him/her
Start statin therapy for secondary prevention in patients with documented atherosclerotic artery. In patients with life expectancy <2
years, terminal dementia, or > 85 years (less likely to benefit, side effects), treatment should be decided by informing the patient/
relatives with the shared decision-making principle
Legend: Issues are classified by decreasing prevalence. The reason associated with the indication is displayed in parentheses, when available. An indication
could address several different issues.
aIncludes issues related to administration timing, dosage, treatment duration, medication formulation.
bIncludes potential prescribing omissions and co-prescription required because of another medication.
cPrescribing measure (all others are prescribing criteria).
dIncludes indications related to cognitive function and physical condition.
eClinical or paraclinical monitoring. Includes issues related to narrow therapeutic index.
fNo proven efficacy, or questionable efficacy/safety profile, as defined by FORTA class C: “Drugs with questionable efficacy/safety profiles in the elderly
which should be avoided or omitted in the presence of too many drugs, absence of benefits or emerging side effects; explore alternatives.”31
gIncludes patient preferences, satisfaction, and shared-decision making.
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Discussion
Among 16 sets of prescribing indications for common and
clinically significant chronic conditions in older adults
identified through this literature review, most were criteria,
while quality measures represented less than 6% of indica-
tions. The most frequently addressed medications were
antihypertensives, analgesics/antirheumatics, antiplatelets/
anticoagulants, and antidepressants. Most indications
focused on drug-disease interactions, adverse drug events,
administration, availability of a better therapeutic alterna-
tive, and (co-)prescription omission. Prescribing indica-
tions that considered patient perspectives were rare, and
prescribing by multiple healthcare providers was not
addressed.
Several key themes emerged from this review. First, we
identified numerous prescribing criteria for older adults,
but relatively few quality measures. Prescribing criteria,
similar to other recommendations to decrease low-value
care (e.g., Choosing Wisely),36 are an important first step
to improve appropriate prescribing and deprescribing.
However, criteria have not yet yielded broad changes in
clinical practice.37 This could be due to the absence of a
systematic implementation approach, lack of specificity in
the indications to support point-of-care decision-making,
disagreement with the indications by patients and/or provi-
ders, or lack of incentive for noncompliant prescribers.37
Future initiatives should include strategies to facilitate
implementation. Performance measures should also be
developed, in addition to prescribing criteria, since they
have greater specificity and potential to impact prescribing
practices.13
Second, monitoring was rarely addressed in the indica-
tions. Only one prescribing set systematically addressed
this issue.32 However, clinical and/or paraclinical monitor-
ing is critical for starting or discontinuing a medication.
This includes identifying adverse events due to a new med-
ication, tapering according to withdrawal symptoms, and
tracking reemergent symptoms after a medication is dis-
continued.38 Prescribing indications for chronic conditions
are more likely to be successfully implemented and sus-
tained if they specify a clear monitoring and tapering plan
to guide providers and patients. Future measures should
consider this crucial issue.
Third, most indications focused on potentially inap-
propriate prescribing, with almost a quarter addressing
drug-disease interaction, while only 20% of indications
focused on when to start a medication. This suggests
greater awareness that doing “more” by prescribing more
medications is not always better39 for older adults, espe-
cially those with multimorbidity. Prescribing indications
that specifically address multimorbidity, age and life
expectancy, may improve appropriate prescribing and
deprescribing, while applying single disease-based guide-
lines based on trials that often excluded multimorbid
patients,40,41 and that focus on treatment intensification
rather than deintensification,42 may be inappropriate and
detrimental to such patients.6,7
Fourth, prescribing by multiple providers was not
addressed, despite that older adults with multimorbidity
usually have several specialist providers. Specialists often
focus on optimizing single conditions in isolation and may
thus overprescribe or inappropriately prescribe particularly
in patients with multimorbidity and polypharmacy. Primary
care physicians remain critical in these patients because of
their predominant role in managing multimorbidity, pre-
scribing chronic medications, and maintaining accurate
medication reconciliation. Future prescribing indications
should be developed specifically for multimorbid patients
and address challenges due to multiple providers.
Patient perspective was also rarely addressed in the indi-
cations, whereby only one study used patient interviews to
develop indications.29 Patient preferences on topics such as
administration time, pharmaceutical formulation, and
tapering plan, and active involvement to monitor adverse
drug events or withdrawal symptoms of medication discon-
tinuation, are critical for most prescribing issues and should
be addressed in future indications.
Prescribing should also be discussed with patients when
there is limited evidence such as older or multimorbid
patients who are frequently excluded from trials. Identify-
ing patient health priorities and prioritizing their success
through shared decision-making could also reduce treat-
ment burden.43 This is particularly important in the pres-
ence of multimorbidity given the prevalence and severity of
polypharmacy among these patients. Disregarding patient
preferences may reduce adherence and successful
deprescribing.38,44,45
Finally, while half the prescribing sets, including 40% of
all indications, adapted criteria or measures developed pre-
viously, there was little evidence of critical revision or
removal of indications. While most prescribing sets men-
tioned assessing the level of evidence, it was not always
provided, and it was graded in only two prescribing sets.8,28
Although some indications remain relevant, such as avoid-
ing duplicate medications, others may require modification
with emerging evidence. Regular updates are conducted for
some indications, such as the Beers criteria,8 but this is not
universal among all current indications. To ensure a robust
set of valid measures, future contributions should routinely
employ standard evidence for grading practices, assess the
most recent evidence, and revise or remove prescribing
indications as appropriate.
Strengths and limitations
Our work has several limitations. First, we did not review
unpublished or ongoing studies because protocols of non-
interventional studies are rarely published in advance and
thus difficult to identify. Second, we focused on chronic
medications since these comprise the majority of pre-
scribed medications and may require modification in
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dynamic disease states. Thus, our findings may not apply to
indications for prescribing in acute conditions. Third, we
analyzed only prescribing indications related to select
chronic conditions to better focus on the most frequent and
relevant issues in older adults. Fourth, the review was con-
ducted by a single author, although all classification issues
were discussed with the senior authors. Finally, we did not
review disease-specific guidelines published by specialty
societies to assure the completeness of the indications.
Our study has several strengths. First, we performed a
comprehensive review that included Ovid/MEDLINE and
EMBASE, and reference lists from the selected articles,
reducing the likelihood of missed prescribing sets. Second,
we used a broad search strategy that focused on the most
common chronic conditions yet did not restrict search
terms to those conditions to increase the probability of
identifying all relevant prescribing sets. Third, we used a
comprehensive and systematic framework to classify issues
addressed by the indications. Finally, we included only
criteria and measures published in 2015 or later to reflect
the most recent evidence.
Conclusion
Our review identified hundreds of criteria, but few mea-
sures focused on appropriate prescribing for the most com-
mon and clinically significant chronic conditions affecting
older adults. Indications, including both criteria and mea-
sures, primarily focused on when to deprescribe or adapt
prescribing to prevent adverse consequences. While
disease-specific guidelines often address intensification,42
our review demonstrates that prescribing indications for
older persons appropriately emphasize deintensification.
However, several important issues related to potentially
inappropriate prescribing were rarely addressed in the indi-
cations, including patient perspective and prescribing by
multiple providers. Indications addressing drug-disease
interactions were frequent, highlighting the importance of
considering all comorbidities and medications when adjust-
ing a patient’s medication regimen. By identifying critical
yet rarely addressed issues in current prescribing indica-
tions, this review can help guide the development of future
quality measures to improve prescribing for older adults
with multimorbidity and understand potential barriers to
implementation.
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